Lowenthal’s tenure as an officer and employee concluded on July 6. The company provided no specific explanation regarding his departure. Casale, who previously served as the firm’s president, brings over 25 years of experience in commercial leadership and biopharmaceutical business to the top role.
Prior to his time at ARS, Casale held the position of chief commercial officer at Dynavax Technologies and managed marketing and sales operations for Depomed. Board members expressed confidence that his background will sharpen the company’s focus on long-term value creation and the ongoing commercialization of its primary product, neffy.
Comments (0)
No comments yet. Be the first!